London, United Kingdom (CU)_ Apollo Therapeutics, a biopharmaceutical business specializing in translational biology and asset-centric drug development, revealed that it has entered into a new strategic cooperation with King’s College London. Along with Imperial College London, University College London, and the University of Cambridge, King’s College London also joins Apollo as a leading worldwide research partner.
The cooperation will…
